KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax: 2024

Historic Long-Term Deferred Tax for Recursion Pharmaceuticals (RXRX) over the last 1 years, with Dec 2024 value amounting to $1.9 million.

  • Recursion Pharmaceuticals' Long-Term Deferred Tax was N/A to $957,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $957,000, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2024, which is N/A change from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Long-Term Deferred Tax is $1.9 million.
  • Recursion Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $1.9 million for FY2024, and its period low was $1.9 million during FY2024.
  • Its 1-year average for Long-Term Deferred Tax is $1.9 million, with a median of $1.9 million in 2024.